Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GamLPV dosing and application methods in healthy volunteers
NCT04036526Phase 2Unknown
- Start
- Jun 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lopinavir + ritonavir in pertussis (2 arms). Primary endpoints: Selection of methods of applications at 140 days and Selection of dosing schedules at 140 days. Status: unknown.
02
Drugs
lopinavir + ritonavir
03
Conditions
pertussis
Beyond the preview
Go deeper on NCT04036526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04036526.